Advertisement

The Role of Hemopoietic Cytokines in the Myelodysplastic Syndromes

  • Peter L. Greenberg

Abstract

Hemopoietic cytokines have been used to attempt to improve the cytopenias and to modulate the pathogenetic mechanisms in myelodysplastic syndromes (MDS). Neutropenia has generally been alleviated in 80–90% of MDS patients with G-CSF and GM-CSF therapy in numerous short-term and several long-term trials. A recent multi-institutional Phase III randomized trial of G-CSF vs. observation in RAEB/RAEB-T subtypes of MDS demonstrated that G-CSF caused no alteration in the incidence or rate of evolution to AML. Survival in RAEB-T patients was the same in both groups; however, RAEB patients receiving G-CSF had decreased survival. This effect was apparent only in the increased number of “high-risk” patients in the G-CSF group. Several trials utilizing the combination of GM-CSF plus low dose AraC have demonstrated either good responses, stable disease or disease progression in approximately equal thirds of the patients, with a high degree of treatment-related toxicity. No increased survival was shown compared to prior studies using either agent alone. These data indicate that other approaches are needed to attempt to alter the natural history of MDS. Cytopenias have been modestly improved with IL-3 as have thrombocytopenias in a minor proportion of patients with IL-6 treatment, although substantial toxicity was noted at high doses. Erythropoietin (Epo) in relatively high doses has improved the anemias in only approximately 20–25% of MDS patients. Epo combined with G-CSF has demonstrated erythropoietic synergistic activity and has led to an approximate 40–45% erythroid response rate in MDS. The biologic effects of the hemopoietic cytokines provide a basis for planning current clinical trials in this problematic disease.

This paper will focus on recent advances in attempts to modulate the cytopenias and pathogenetic mechanisms of myelodysplastic syndromes (MDS) by treatment with hemopoietic cytokines. Therapeutic results will be placed in the context of newer clinical and biological approaches for stratifying MDS.

Keywords

Acute Myeloid Leukemia Myelodysplastic Syndrome Recombinant Human Erythropoietin Restriction Fragment Length Polymorphism Erythroid Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett JM, Catovsky D, Daniel MT, et al: FAB Cooperative Group: Proposal for the classification of the myeiodysplastic syndromes. Br J Haematol 1982; 51:189–199.PubMedGoogle Scholar
  2. 2.
    Greenberg, PL: Treatment of MDS with hemopoietic growth factors. Semin Oncol 1992; 19:106–114.PubMedGoogle Scholar
  3. 3.
    Sanz GF, Sanz MA, Vallespi T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myeiodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395–408.PubMedGoogle Scholar
  4. 4.
    Greenberg P: In vitro hemopoietic cell culture studies in MDS. Sem Oncol 1992; 19:34–46.Google Scholar
  5. 5.
    Pierre R, Catovsky D, Mufti G, et al: Clinical cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogeniet 1990; 44:15–26.CrossRefGoogle Scholar
  6. 6.
    Morel P, Hebbar M, Lai JL, et al: Cytogenetic analysis has strong independent prognostic value in de novoMDS and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7:1315.PubMedGoogle Scholar
  7. 7.
    Toyama K, Ohyashiki K, Yoshida Y, et al: Clinical implications of chromosomal abnormalities in 401 patients with MDS: A multicentric study in Japan. Leukemia 1993; 7:499–508.PubMedGoogle Scholar
  8. 8.
    Metcalf D: The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 1986; 67:257–267.PubMedGoogle Scholar
  9. 9.
    Miyauchi J, Kelleher CA, Yang YC, et al: The effects of three recombinant growth factors, IL3, GM-CSF and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987; 76:657–663.Google Scholar
  10. 10.
    Vellenga E, Young DC, Wagner K, et al: The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69:1771–1776.PubMedGoogle Scholar
  11. 11.
    Vadhan-Raj S, Keating M, LeMaistre A, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Eng J Med 1987; 317:1545–1552,CrossRefGoogle Scholar
  12. 12.
    Antin JH, Smith BR, Holmes W, et al: Phase I/II study of recombinant granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72:705–713.PubMedGoogle Scholar
  13. 13.
    Ganser A, Volkers B, Greher J, et al: Recombinant human GM-CSF in patients with MDS- A Phase I/II trial. Blood 1989; 73:31–37.PubMedGoogle Scholar
  14. 14.
    Herrmann F, Lindemann A, Klein H, et al: Effect of recombinant GM-CSF in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989; 3:335–338.PubMedGoogle Scholar
  15. 15.
    Thompson JA, Lee DJ, Kidd P, et al: Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with MDS: Toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7:629–637.PubMedGoogle Scholar
  16. 16.
    Gradishar W, Le Beau MM, O’Laughlin R, et al: Clinical and cytogenetic responses to GM-CSF in therapy-related myelodysplastic syndrome. Blood 1992; 80:2463–2470.PubMedGoogle Scholar
  17. 17.
    Willemze R, van der Lely N, Zwierzina H, et al: A randomized phase I/II multicenter study of recombinant human GM-CSF therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Hematol 1992; 64:173–180.PubMedCrossRefGoogle Scholar
  18. Schuster MW, Thompson JA, Larson R, et al: Randomized trial of subcutaneous GM-CSF versus observation in patients with myelodysplastic syndrome or aplastic anemia. Proc Am Soc Clin Oncol 1990, p. A793.Google Scholar
  19. 19.
    Economopoulos T, Papageorgiou E, Stathakis N, et al: Treatment of myelodysplastic syndromes with human granulocyte-macrophage colony-stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside. Eur J Haematol 1992; 49:138–142.PubMedCrossRefGoogle Scholar
  20. 20.
    Gerhartz HH, Marcus R, Delmer A, et al: A randomised Phase II study of low-dose cytosine arabinoside plus GM-CSF in MDS with a high risk of developing leukemia. Leukemia 1994; 8:16–23.PubMedGoogle Scholar
  21. 21.
    Miller KB, Kim K, Morrison FS, et al: Evaluation of low dose Ara C vs. supportive care in the treatment of MDS: An intergroup study by the ECOG and SWOG. Blood 1988; 72(suppl 1):215A.Google Scholar
  22. 22.
    Negrin RS, Haeuber DH, Nagler A, et al: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. Annals Internal Med 1992; 110:976–984.Google Scholar
  23. 23.
    Negrin RS, Nagler A, Kobayashi Y, et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 1992; 78:36–43.Google Scholar
  24. 24.
    Yoshida Y, Hirashima K, Asano S, et al: A Phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991; 78:378–384.PubMedCrossRefGoogle Scholar
  25. 25.
    Greenberg P, Taylor K, Larson R, Koeffler P, Negrin R, et al: Phase III randomized multicenter trial of G-CSF vs. observation for MDS. Blood 1993; 82(suppl l):196a.Google Scholar
  26. 26.
    Ganser A, Seipelt G, Lindemann A, et al: Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 6:455Google Scholar
  27. 27.
    Kurzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991; 9:1241–1250.PubMedGoogle Scholar
  28. 28.
    Ganser A, Ottmann OG, Seipelt G, et al: Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993; 7:696–701.PubMedGoogle Scholar
  29. 29.
    Gordon MS, Nemunaitis J, Hoffman R, et al: A Phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85:3066–3076.PubMedGoogle Scholar
  30. 30.
    Jacobs A, Janowska-Wieczorek A, Caro J, et al: Circulating erythropoietin in patients with MDS. Br J Haematol 1989; 73:36–39.PubMedCrossRefGoogle Scholar
  31. 31.
    Bessho M, Jinnai I, Matsuda A: Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 1990; 8:445–458.PubMedCrossRefGoogle Scholar
  32. 32.
    Stebler C, Tichelli A, Dazzi H, et al: High-dose recombinant human erythropoietin for treatment of anemia in MDS and paroxysmal nocturnal hemoglobinuria: A pilot study. Exp Hematol 1990; 18:1204–1208.PubMedGoogle Scholar
  33. 33.
    Stein R, Abels R, Krantz S: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78:1658–1665.PubMedGoogle Scholar
  34. 34.
    van Kamp H, Prinsze-Postema T, Kluin PM, et al: Effect of subcutaneously administered human recombinant erythropoietin in patients with myelodysplasia. Brit J Haematol 1991; 78:488.CrossRefGoogle Scholar
  35. 35.
    Hellstrom E, Birgegárd G, Lockner D, et al: Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 1991; 47:355–360.PubMedCrossRefGoogle Scholar
  36. 36.
    Schouten HC, Vellenga E, van Rhenen D, et al: Recombinant human erythropoietin for patients with MDS. Blood 76:317, 1990Google Scholar
  37. 37.
    Bowen D, Culligan D, Jacobs AJ: The treatment of anaemia in the MDS with recombinant human erythropoietin. Brit J Haematol 1991; 77:419.CrossRefGoogle Scholar
  38. 38.
    Merchav S, Nielsen OJ, Rosenbaum H, et al: In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myeiodysplastic syndromes. Leukemia 1990; 4:771–774.PubMedGoogle Scholar
  39. 39.
    Greenberg, PL, Negrin R, Ginzton N: G-CSF synergizes with erythropoietin for enhancing erythroid colony formation in myeiodysplastic syndromes. Blood 1991; 78:38a.Google Scholar
  40. 40.
    Negrin RS, Stein R, Doherty K, et al: Treatment of the anemias of MDS using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82:737–743.PubMedGoogle Scholar
  41. 41.
    Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al: A combination of G-CSF and erythropoietin may synergistically improve the anaemia in patients with MDS. Leuk Lymph 1993; 11:221–228.CrossRefGoogle Scholar
  42. 42.
    Hellstrom-Lindberg E, Negrin R, Stein R, et al: Prediction of response to G-CSF and Epo treatment for the anemia of myeiodysplastic syndromes. Leuk Res 1994; 18 (Suppl):53a.CrossRefGoogle Scholar
  43. 43.
    Negrin RS, Stein R, Doherty K, Cromwell J, Vardiman J, Krantz S, Greenberg P: G-CSF plus erythropoietin for the maintenance treatment of the anemia of myeiodysplastic syndromes. Blood 1996; 87:4076–4081.PubMedGoogle Scholar
  44. 44.
    Janssen JWG, Buschle M, Layton M, et al: Clonal analysis of MDS: Evidence of multipotent stem cell origin. Blood 1989; 73:248–254.PubMedGoogle Scholar
  45. 45.
    Gilliland DG, Blachard KL, Levy J, Perrin S, Bunn H: Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. PNAS 1991; 88:6848.PubMedCrossRefGoogle Scholar
  46. 46.
    Vadhan-Raj S, Broxmeyer HE, Spitzer G, et al: Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human GM-CSF in a patient with therapy-related myeiodysplastic syndrome. Blood 1989; 74:1491–1498.PubMedGoogle Scholar
  47. 47.
    Kohler S, Busque L, DeHart D, Le Beau M, Negrin R, Ganser A, Greenberg P, Gilliland DG: Clonality analysis in myelodysplasia patients treated with G-CSF. Blood 1993; 82(suppl l):376a.Google Scholar
  48. 48.
    Kaushansky K, Lok L, Holly R, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature 1994; 369:568.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • Peter L. Greenberg
    • 1
    • 2
  1. 1.Hematology DivisionStanford University Medical CenterUSA
  2. 2.VA Palo Alto Health Care SystemPalo AltoUSA

Personalised recommendations